Literature DB >> 21531003

Predictors of tumor response after preoperative chemoradiotherapy for rectal adenocarcinomas.

Nathalie Guedj1, Frédéric Bretagnol, Pierre-Emmanuel Rautou, Lydia Deschamps, Dominique Cazals-Hatem, Pierre Bedossa, Yves Panis, Anne Couvelard.   

Abstract

The ability to predict response after chemoradiotherapy in rectal adenocarcinoma may allow selecting patients to whom less invasive surgical treatment could be proposed. Tumor hypoxia has been implicated in the mechanisms of resistance to chemoradiotherapy in several malignancies. The aim was to identify morphological criteria and molecular markers of hypoxia associated with chemoradiotherapy response. Clinicopathologic data from 61 patients (35 male, 60.5 ± 10 years) undergoing rectal cancer resection after neoadjuvant chemoradiotherapy were collected. Pretreatment biopsies, available for 40 patients, were immunostained for hypoxia markers (carbonic anhydrase 9, glucose transporter 1, chemokine receptor 4) and microvascular density determination. Mean tumor size was 2.7 ± 1.6 cm. Twenty-one patients (34%) were considered as responders, that is, having significant or complete primary tumor regression without lymph node metastasis. Compared to other patients, responders had significantly more often flat tumors with or without ulceration (57% versus 18%, P = .01) and less vascular and/or neural invasions (9% versus 65%, P < .0001) or tumor necrosis (9% versus 41%, P < .01), respectively. Regarding pretreatment biopsies, carbonic anhydrase 9 expression was significantly lower in responders (7% versus 46%, P = .012). This study showed that tumor necrosis as an overexpression of carbonic anhydrase 9 was an effective molecular marker of postchemoradiotherapy response. This might suggest a key role of hypoxia in resistance mechanisms of chemoradiotherapy in rectal adenocarcinoma. This study highlighted the importance of predictive criteria to chemoradiotherapy response in proposing to selected patients an alternative treatment (eg, local resection) to more radical surgery.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21531003     DOI: 10.1016/j.humpath.2011.01.015

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  10 in total

1.  Selecting patients for hyperthermia combined with preoperative chemoradiotherapy for locally advanced rectal cancer.

Authors:  Sang-Won Kim; Ji Woon Yea; Jae Hwang Kim; Mi Jin Gu; Min Kyu Kang
Journal:  Int J Clin Oncol       Date:  2017-11-13       Impact factor: 3.402

2.  The critical role of dysregulated FOXM1-PLAUR signaling in human colon cancer progression and metastasis.

Authors:  Dawei Li; Ping Wei; Zhihai Peng; Chen Huang; Huamei Tang; Zhiliang Jia; Jiujie Cui; Xiangdong Le; Suyun Huang; Keping Xie
Journal:  Clin Cancer Res       Date:  2012-11-07       Impact factor: 12.531

3.  Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma.

Authors:  Marie Grøn Saelen; Anne Hansen Ree; Alexandr Kristian; Karianne Giller Fleten; Torbjørn Furre; Helga Helseth Hektoen; Kjersti Flatmark
Journal:  Radiat Oncol       Date:  2012-09-27       Impact factor: 3.481

4.  Immunohistochemical detection of CD133 is associated with tumor regression grade after chemoradiotherapy in rectal cancer.

Authors:  Kumiko Hongo; Shinsuke Kazama; Eiji Sunami; Nelson H Tsuno; Koki Takahashi; Hirokazu Nagawa; Joji Kitayama
Journal:  Med Oncol       Date:  2012-01-14       Impact factor: 3.064

5.  Review of the development of DNA methylation as a marker of response to neoadjuvant therapy and outcomes in rectal cancer.

Authors:  Jeremy S Williamson; Dean A Harris; John Beynon; Gareth J S Jenkins
Journal:  Clin Epigenetics       Date:  2015-07-22       Impact factor: 6.551

6.  Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer.

Authors:  Helga Helseth Hektoen; Kjersti Flatmark; Yvonne Andersson; Svein Dueland; Kathrine Røe Redalen; Anne Hansen Ree
Journal:  BMC Cancer       Date:  2015-07-24       Impact factor: 4.430

Review 7.  Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors.

Authors:  Olga Sedlakova; Eliska Svastova; Martina Takacova; Juraj Kopacek; Jaromir Pastorek; Silvia Pastorekova
Journal:  Front Physiol       Date:  2014-01-08       Impact factor: 4.566

8.  Evaluation of 18F-FMISO PET and 18F-FDG PET Scans in Assessing the Therapeutic Response of Patients With Metastatic Colorectal Cancer Treated With Anti-Angiogenic Therapy.

Authors:  Sze Ting Lee; Niall Tebbutt; Hui Kong Gan; Zhanqi Liu; John Sachinidis; Kunthi Pathmaraj; Andrew Mark Scott
Journal:  Front Oncol       Date:  2021-03-17       Impact factor: 6.244

Review 9.  Predicting response to neoadjuvant chemoradiotherapy in rectal cancer: from biomarkers to tumor models.

Authors:  Moying Li; Qiyun Xiao; Nachiyappan Venkatachalam; Ralf-Dieter Hofheinz; Marlon R Veldwijk; Carsten Herskind; Matthias P Ebert; Tianzuo Zhan
Journal:  Ther Adv Med Oncol       Date:  2022-02-21       Impact factor: 8.168

Review 10.  Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis.

Authors:  Simon J A van Kuijk; Ala Yaromina; Ruud Houben; Raymon Niemans; Philippe Lambin; Ludwig J Dubois
Journal:  Front Oncol       Date:  2016-03-29       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.